Who
Sandeep Laumas
Director
Company insider
Files Form 4 as: Director, Unicycive Therapeutics; Director, BioXcel Therapeutics; CFO and CBO, Instil Bio; CEO, Executive Chairman, 9 Meters Biopharma.
In numbers
- Trades disclosed
- 58
- Buys
- 9
- Sells
- 1
- Bought
- $39K
- Sold
- $702K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 12 Mar 2018
- Last trade
- 14 May 2026
- Last filed
- 28 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 28 Jul 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,941 at $0.00 | filing |
| 14 May 2026filed 28 Jul 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,941 at $0.00 | filing |
| 14 May 2026filed 15 Jun 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 14 May 2026filed 15 Jun 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
| 14 May 2026filed 15 Jun 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 14 May 2026filed 15 Jun 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —17,000 at $0.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —13,000 at $0.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | TIL Instil BioBiotechnology | SEC FORM 4 Code M | $197K17,000 at $11.60 | filing |
| 10 Sep 2025filed 12 Sep 2025 | TIL Instil BioBiotechnology | SEC FORM 4 Code M | $165K13,000 at $12.68 | filing |
| 10 Sep 2025filed 12 Sep 2025 | TIL Instil BioBiotechnology | SEC FORM 4 Sold | $404K17,539 at $23.04 | filing |
| 10 Sep 2025filed 12 Sep 2025 | TIL Instil BioBiotechnology | SEC FORM 4 Sold | $298K12,461 at $23.88 | filing |
| 28 Jul 2025filed 30 Jul 2025 | UNCY Unicycive Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,200 at $0.00 | filing |
| 25 Apr 2025filed 28 Apr 2025 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —44,851 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.